Abstract
The treatment strategies for acute leukemia are undergoing very rapid change. Particularly for last 10 years, due to the rapid development of molecular targeted therapy and cell/gene therapies, the role of HSCT in the treatment scheme of acute leukemia has been changing. In the author's view, these recent changes should secure the role of HSCT in the comprehensive treatment scheme of acute leukemia. By appropriately combining the new agents with HSCT, therapy for acute leukemia is anticipated to become more effective. HSCT will provide the centerpiece for the treatment scheme, by setting up the "platform" for further interventions. Keeping these changes in mind, transplant physicians should now be exploring new areas of research such as interactions between these new agents and GVHD/GVL.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
